Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million ...

Hikma Pharmaceuticals KSA, announced the expansion of its strategic partnership with the Saudi Gastroenterology Association ...

(Alliance News) - Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form business. Denmark-based Xellia Pharmaceuticals ApS. Xellia's FDF ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Unfortunately, that's been the case for longer term Hikma Pharmaceuticals PLC (LON:HIK) shareholders, since the share price is down 24% in the last three years, falling well short of the market ...

Both central banks are expected to announce that interest rates will remain unchanged.

Hikma Pharmaceuticals (HIK – Research Report) received a Buy rating and a p2,400.00 price target from Berenberg Bank analyst Victoria Lambert yesterday. The company’s shares closed yesterday ...

But if you try your hand at stock picking, you risk returning less than the market. Unfortunately, that's been the case for longer term Hikma Pharmaceuticals PLC (LON:HIK) shareholders, since the ...